A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J.
Chiocca EA, et al. Among authors: fisher jd.
Mol Ther. 2004 Nov;10(5):958-66. doi: 10.1016/j.ymthe.2004.07.021.
Mol Ther. 2004.
PMID: 15509513
Free article.
Clinical Trial.